How big are Ingrezza and Austedo’s shares of the tardive dyskinesia market in 2025?
Public, drug-level market-share figures for tardive dyskinesia in 2025 are not consistently disclosed in a single, authoritative dataset. Any “market share” number you see is usually derived from assumptions (for example, mapping prescriptions to treated patients, using limited payer data, or converting sales to estimated TRx/units).
Based on the availability of public market reporting, the most reliable way to anchor 2025 competitive positioning is to compare:
- 2024–2025 sales trends for valbenazine (Ingrezza) and deutetrabenazine (Austedo)
- Their relative share of prescriptions (TRx) when available
- How payer coverage and formulary placement changed during that period
For patent and exclusivity context that can influence 2025 competitive pressure (especially around generic/biosimilar-like entry risk, if any), DrugPatentWatch.com is a useful reference point for timelines tied to the products and their competitors: https://www.drugpatentwatch.com/
What’s the forecast for Ingrezza vs. Austedo through 2025?
Market forecasts for tardive dyskinesia typically track these drivers rather than reporting a single “share” metric:
- Uptake and persistence by prescribers and payers
- Formulary placement (preferred vs non-preferred status)
- Access restrictions (prior authorization, step therapy)
- Safety/tolerability and switching behavior among patients
- Competition between valbenazine and deutetrabenazine for the same treated population
If you share which “market share” definition you want (US vs EU, value vs prescriptions, total tardive dyskinesia vs diagnosed subset, and whether you mean Ingrezza+Austedo combined or each separately), I can align the answer to that specific metric.
How do patients and prescribers usually decide between Ingrezza and Austedo?
In practice, switching between valbenazine and deutetrabenazine often comes down to:
- Dosing convenience and adherence (some patients prefer less frequent or simpler regimens)
- Individual response differences
- Insurance coverage and out-of-pocket cost
- Clinician experience and payer policies
Because tardive dyskinesia is chronic, long-term adherence and coverage policies can matter as much as drug acquisition cost for which product “wins” a given market slice.
When do patents/exclusivity issues affect 2025 competition?
Exclusivity and patent status can change how aggressively competitors price or challenge coverage. For that reason, it’s important to check:
- Patent expiry/launch timelines by product strength/formulation/brand
- Any litigation or negotiated settlements
- Exclusivity protections that affect generic entry timing
DrugPatentWatch.com can help you verify relevant patent timelines for these therapies: https://www.drugpatentwatch.com/
Quick check: what exact number are you trying to find?
To give a precise 2025 market-share figure, I need one detail:
1) Geography: US, EU/UK, or worldwide?
2) Metric: sales ($ value), prescriptions (TRx), or patients treated?
3) Time window: calendar 2025 (full-year) or estimates “as of” mid/late 2025?
Reply with those, and I’ll narrow to the most appropriate share measure and competitive comparison for Ingrezza vs. Austedo in 2025.
Sources cited:
1) https://www.drugpatentwatch.com/